Belvedere Trading’s Ironwood Pharmaceuticals IRWD Stock Holding History

Belvedere Trading’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,600	Closed	-$31.4K	–	804
2024 Q1	$31.4K	Buy	+3,600	New	+$43.7K	﹤0.01%	544

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Belvedere Trading's IRWD Position: Q2 2021 in Review

Belvedere Trading sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2021, closing a stake of 18,750 shares — an estimated $210K sold.

Belvedere Trading first reported a position in IRWD in Q1 2021 and held it in 1 quarter. The position peaked at $210K in Q1 2021. 208 funds tracked by Wall St. Rank hold IRWD as of Q2 2021.

Belvedere Trading reported no remaining Ironwood Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Belvedere Trading sold 18,750 Ironwood Pharmaceuticals shares in Q2 2021, an estimated $210K.
Belvedere Trading first reported a position in Ironwood Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Belvedere Trading's Ironwood Pharmaceuticals position peaked at $210K in Q1 2021.
208 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2021.

Based on Belvedere Trading's 13F filing for Q2 2021, filed 23 Jul 2021.